Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.
Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check6 days agoChange DetectedNew entries reflect updated study record dates (e.g., last update posted). There are no changes to core content such as eligibility criteria, outcomes, or enrollment.SummaryDifference0.2%
- Check13 days agoChange DetectedLocations now appear as a dedicated section with Florida listed as a site; the Florida Locations header and HHS Vulnerability Disclosure were removed in revision v3.3.3.SummaryDifference0.2%
- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows a revision label: v3.3.2 replacing v3.3.1 in the site footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check42 days agoChange DetectedBranding for the Moffitt Cancer Center Clinical Trials website and a 'Helpful Links Provided by' section were added, and the revision label updated from v3.2.0 to v3.3.1.SummaryDifference0.2%
- Check49 days agoChange DetectedRemoved the site-wide government funding/operating status notice from the page.SummaryDifference0.4%
- Check63 days agoChange DetectedThe study record for NCT03514017 shows updated details such as the last update date (now 2025-09-22) and associated study dates, including enrollment and results posting timeline.SummaryDifference0.4%
Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.